Céline Montavon Sartorius

Pertuzumab as second‑ or later‑line therapy for human epidermal growth factor receptor 2‑positive metastatic breast cancer: A clinical experience

C. Leo, E. Biskup, M. Vetter, 2021, Molecular and clinical oncology.